Key statistics
As of last trade, Editas Medicine Inc (8EM:MUN) traded at 1.50, 63.99% above the 52 week low of 0.9162 set on Apr 09, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 1.50 |
|---|---|
| High | 1.50 |
| Low | 1.50 |
| Bid | 1.52 |
| Offer | 1.56 |
| Previous close | 1.50 |
| Average volume | 2.27k |
|---|---|
| Shares outstanding | 97.62m |
| Free float | 97.35m |
| P/E (TTM) | -- |
| Market cap | 176.69m USD |
| EPS (TTM) | -2.38 USD |
Data delayed at least 15 minutes, as of Feb 10 2026 07:01 GMT.
More ▼
Announcements
- Editas Medicine Announces Third Quarter 2025 Results and Business Updates
- Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025
- Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
- Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences
- Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
- Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate
- Editas Medicine to Participate in Upcoming Investor Conferences
- Editas Medicine Announces Second Quarter 2025 Results and Business Updates
- Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June
- Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June
More ▼
